

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute, and is not intended to be, an invitation or offer to acquire, purchase or subscribe for, or offer to sell or a solicitation of any offer to buy securities in Hong Kong, the United States or elsewhere. Any such offer or invitation will be made only in jurisdictions in which it may be legally and validly made. Securities may not be offered or sold in the United States absent registration with the U.S. Securities and Exchange Commission (the “SEC”) or an exemption from registration. A “shelf” registration statement on Form F-3 (File No. 333-257609), which includes a prospectus (the “Base Prospectus”), relating to the public offering of certain securities of Legend Biotech Corporation (“Legend Biotech”), including ordinary shares, par value US\$0.0001 per share, of Legend Biotech represented by American Depositary Shares (“ADSs”), has been previously filed by Legend Biotech with the SEC and is effective. Any public offering of ADSs to be made in the United States will be made solely by means of a prospectus supplement to the Base Prospectus that may be obtained, when available, from Legend Biotech and that will contain or incorporate by reference detailed information about the company and management, as well as financial statements of Legend Biotech.

Neither this announcement nor any content contained herein shall form the basis of any contract or commitment whatsoever.



Genscript Biotech Corporation
金斯瑞生物科技股份有限公司*
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)

**COMPLETION OF THE REGISTERED DIRECT OFFERING
OF LEGEND BIOTECH**

Reference is made to the announcement and the overseas regulatory announcement of the Company dated 8 May 2023 relating to Registered Direct Offering of Legend Biotech (the “**Previous Announcements**”). Unless otherwise defined, terms used in this announcement shall have the same meanings given them in the Previous Announcements.

The Board is pleased to announce that Legend Biotech, a non-wholly owned subsidiary of the Company, whose shares are listed by way of ADSs on the Nasdaq Global Select Market in the United States, informed the Company that the closing of the Registered Direct Offering took place on 11 May 2023 (U.S. Eastern Time, after trading hours in Hong Kong). Legend Biotech issued 5,468,750 ADSs in the Registered Direct Offering, each representing two Legend Biotech Shares, at a purchase price of US\$64.00 per ADS (equivalent to approximately HK\$502.4 per ADS).

Immediately upon the completion of the Registered Direct Offering, the shareholding of the Company in Legend Biotech has been diluted and reduced to 49.76% of outstanding Legend Biotech Shares, without taking into account the future allotment, issuance, exercise and vesting of the ESOP Shares and assuming the Legend Warrant has not been exercised.

As disclosed in the “Major Shareholders and Related Party Transactions” section of Legend Biotech’s annual report on Form 20-F filed with the SEC on 30 March 2023 and as of the date of this announcement, Dr. Zhang Fangliang, being one of our Controlling Shareholders, has voting power over approximately 1.2 million Legend Biotech Shares pursuant to irrevocable proxies granted to him by certain option holders under the

Legend Share Option Scheme, which such proxies became effective upon the exercise of share options pursuant to which such Legend Biotech Shares were issued. On the basis that Dr. Zhang Fangliang, through the Company and such proxies, is entitled to exercise or control the exercise of over 50% of the voting power at general meetings of Legend Biotech, Legend Biotech will continue to be a non-wholly owned subsidiary of the Company. The results of operations and financial position of Legend Biotech will continue to be recorded in the Group's consolidated financial statements.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By Order of the Board
Genscript Biotech Corporation
MENG Jiange
Chairman and Executive Director

Hong Kong, 12 May 2023

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai

** For identification purposes only*